ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2589

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE

Gary P. Sims1, Jeffrey Riggs2, Richard Hanna1, Bhargavi Rajan3, Jodi Karnell1, Kamelia Zerrouki1, Divya Sagar1, Inna Vainshtein3, Erika Farmer4, Meina Liang3, Miguel A. Sanjuan1 and Roland Kolbeck1, 1Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, 2Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, 3MedImmune, LLC, Mountain View, CA, 4Analytical Sciences, MedImmune, LLC, Gaithersburg, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, interferons, mechanisms, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical development for the treatment of SLE and lupus nephritis, targets the interferon alpha receptor 1 (IFNAR1) and blocks IFNAR1-dependent signaling. Here we characterize the mechanistic and functional properties of anifrolumab.
Methods: Binding between anifrolumab and the IFNAR1 was measured by surface plasmon resonance. IFNAR1 internalization on monocytes was assessed by flow cytometry and confocal microscopy. The effect of three mutations in the fragment crystallizable region (Fc) of anifrolumab on Fcγ receptor–dependent cytotoxicity was assessed in antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays. IFNAR1-dependent signaling induced by recombinant human type I IFN (including IFN-α, -β, and -ω) and by plasmacytoid dendritic cell (pDC)–derived type I IFN was assessed in signal transducer and activator of transcription 1 (STAT1) phosphorylation and IFN-stimulated response element–luciferase reporter assays. Production of IFN-α, TNF, IL-6, and IL-8 by stimulated pDC was measured by enzyme-linked immunosorbent assay or Meso Scale Diagnostics, and expression of cluster of differentiation 80 and 86 was measured by flow cytometry. Expression of type I IFN–regulated genes was measured by quantitative PCR. B-cell differentiation in pDC-/B-cell cocultures was assessed by flow cytometry and Ig production.
Results: Anifrolumab blocked type I IFN–dependent IFNAR dimerization and STAT1 phosphorylation with high affinity and specificity. Anifrolumab elicited rapid IFNAR1 internalization and markedly reduced IFNAR1 cell surface levels. Fc mutations on anifrolumab reduced Fcγ receptor–dependent cytotoxicity. Anifrolumab potently inhibited recombinant human type I IFN (including 12 subtypes of α, β, and ω) and pDC-derived type I IFN activities. Anifrolumab suppressed IFN-α, proinflammatory cytokine induction, and upregulation of costimulatory molecules from stimulated pDCs and type I IFN–inducible genes in peripheral blood mononuclear cells. Blockade of IFNAR1 also suppressed plasma cell differentiation and Ig production.
Conclusion: Anifrolumab inhibits type I IFN–dependent signaling by sterically inhibiting and rapidly internalizing IFNAR1 on target cells. Anifrolumab has no detectable CDC or ADCC activity. Blockade of type I IFN signaling suppresses pDC functions and B-cell differentiation. Anifrolumab has the potential to be a promising therapeutic agent for treating SLE and other diseases that demonstrate chronic dysfunctional type I IFN signaling.


Disclosure: G. P. Sims, MedImmune, LLC, 3,AstraZeneca, 1; J. Riggs, MedImmune, LLC, 3,AstraZeneca, 1; R. Hanna, MedImmune, LLC, 3,AstraZeneca, 1; B. Rajan, MedImmune, LLC, 3,AstraZeneca, 1; J. Karnell, MedImmune, LLC, 3,AstraZeneca, 1; K. Zerrouki, MedImmune, LLC, 3,AstraZeneca, 1; D. Sagar, MedImmune, LLC, 3,AstraZeneca, 1; I. Vainshtein, MedImmune, LLC, 3,AstraZeneca, 1; E. Farmer, MedImmune, LLC, 3,AstraZeneca, 1; M. Liang, MedImmune, LLC, 3,AstraZeneca, 1; M. A. Sanjuan, MedImmune, LLC, 3,AstraZeneca, 1; R. Kolbeck, MedImmune, LLC, 3,AstraZeneca, 1.

To cite this abstract in AMA style:

Sims GP, Riggs J, Hanna R, Rajan B, Karnell J, Zerrouki K, Sagar D, Vainshtein I, Farmer E, Liang M, Sanjuan MA, Kolbeck R. Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/functional-and-mechanistic-characterization-of-anifrolumab-a-fully-human-monoclonal-antibody-targeting-the-interferon-alpha-receptor-1-for-the-treatment-of-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-and-mechanistic-characterization-of-anifrolumab-a-fully-human-monoclonal-antibody-targeting-the-interferon-alpha-receptor-1-for-the-treatment-of-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology